Trade Names:JE-Vax- Injection, lyophilized powder for suspension. Each mL contains mouse serum protein less than 50 ng, gelatin approximately 500 mcg, and formaldehyde less than 100 mcg
Trade Names:Ixario- Injection, suspension 6 mcg per 0.5 mL
Inactivated virus vaccine that induces neutralizing antibodies to Japanese encephalitis (JE) virus.
Immunity develops by 10th day after primary vaccination for JE-Vax and by the 7th day for Ixiaro .
Full duration of protection is unknown. A booster dose is recommended after 2 yr of primary series.
Active immunization for JE for persons 1 yr of age and older ( JE-Vax ) and for persons 17 yr of age and older ( Ixiaro ).
History of hypersensitivity to prior dose.JE-Vax
Hypersensitivity to thimerosal; hypersensitivity to proteins of rodent or neural origin.
IM 2 doses of 0.5 mL IM 28 days apart. Complete immunization series at least 1 week prior to exposure to JE virus.JE-VaxAdults and children 3 yr of age and older
Subcutaenously 3 doses of 1 mL subcutaneously on days 0, 7, and 30. The last dose should be given at least 10 days before exposure to JE virus. A booster dose of 1 mL may be given after 2 yr. Only under unusual circumstances, 2 doses may be given a week apart.Children 1 to 3 yr of age
Subcutaenously 3 doses of 0.5 mL subcutaneously on days 0, 7, and 30. An abbreviated schedule of days 0, 7, and 14 may used because of time constraints. A booster dose of 0.5 mL may be given after 2 yr.
Store vaccine between 35° and 46°F. Do not freeze. Use reconstituted JE-Vax within 8 h. During storage of Ixiaro , a clear liquid with a white precipitate can be observed.
None well documented.
None well documented.
Headache (28%); fatigue (11%), migraine (at least 1%).JE-Vax
Nausea (7%); diarrhea, vomiting (2%).
Angioedema of the extremities and face, especially of the lips and oropharynx; erythema multiforme; erythema nodosum; joint swelling; generalized itching.
Tenderness (36%); pain (33%); erythema (10%); induration (8%); edema; pruritus (4%).JE-Vax
Arm soreness and redness (25%); rash (5%).
Myalgia (16%); back pain (1%).
Nasopharyngitis (5%); pharyngolaryngeal pain, upper respiratory tract infection (2%); sinusitis (at least 1%); cough, rhinitis (1%).
Influenza-like illness (12%); pyrexia (3%); rash (1%).JE-Vax
Febrile episode (6%); flu-like symptoms (less than 5%).
Monitor patient for possible adverse reactions. Report suspected adverse reactions following immunization to the Vaccine Adverse Event Reporting System.
Category B ( Ixiaro ), Category C ( JE-Vax ).
Safety and efficacy not established in children younger than 1 yr of age ( JE-Vax ); safety and efficacy not established in children younger than 17 yr of age ( Ixiaro ).
Do not administer to patients with history of acute hypersensitivity to eggs or egg products; anaphylaxis may occur. Anaphylaxis also may occur in persons with no prior history of hypersensitivity to the vaccine components. Ensure that epinephrine injection (1:1,000) is always immediately available.
Immunocompromised patients may have a diminished immune response.
The precise relationship between antibody level and efficacy has hot been established, even though these antibody titers persisted for at least 2 yr after immunization.
Copyright © 2009 Wolters Kluwer Health.